stoxline Quote Chart Rank Option Currency Glossary
  
Avadel Pharmaceuticals plc (AVDL)
15.49  -0.26 (-1.65%)    05-28 16:00
Open: 15.78
High: 16
Volume: 727,631
  
Pre. Close: 15.75
Low: 15.34
Market Cap: 1,489(M)
Technical analysis
2024-05-28 4:20:37 PM
Short term     
Mid term     
Targets 6-month :  20.36 1-year :  22.29
Resists First :  17.43 Second :  19.09
Pivot price 16.1
Supports First :  14.77 Second :  12.28
MAs MA(5) :  15.73 MA(20) :  16.69
MA(100) :  15.72 MA(250) :  14.02
MACD MACD :  -0.5 Signal :  -0.3
%K %D K(14,3) :  20.1 D(3) :  22.1
RSI RSI(14): 38.9
52-week High :  19.09 Low :  9.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ AVDL ] has closed above bottom band by 26.5%. Bollinger Bands are 8.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.02 - 16.1 16.1 - 16.17
Low: 15.11 - 15.21 15.21 - 15.31
Close: 15.31 - 15.46 15.46 - 15.62
Company Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Headline News

Tue, 21 May 2024
Avadel Pharmaceuticals appoints new board member By Investing.com - Investing.com

Thu, 16 May 2024
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives $24.17 Consensus Price Target from Brokerages - MarketBeat

Sun, 12 May 2024
Avadel Pharmaceuticals (NASDAQ:AVDL) PT Raised to $23.00 - Defense World

Thu, 09 May 2024
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Call Transcript - Yahoo Finance

Fri, 12 Apr 2024
This Avadel Pharmaceuticals Insider Reduced Their Stake By 53% - Simply Wall St

Thu, 11 Apr 2024
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Is Expected To Breakeven In The Near Future - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 96 (M)
Shares Float 90 (M)
Held by Insiders 4.6 (%)
Held by Institutions 59 (%)
Shares Short 10,610 (K)
Shares Short P.Month 10,470 (K)
Stock Financials
EPS -2
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.98
Profit Margin 0 %
Operating Margin -128 %
Return on Assets (ttm) -58 %
Return on Equity (ttm) -481.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.29
EBITDA (p.s.) -1.42
Qtrly Earnings Growth 0 %
Operating Cash Flow -129 (M)
Levered Free Cash Flow -78 (M)
Stock Valuations
PE Ratio -7.75
PEG Ratio -2.4
Price to Book value 15.8
Price to Sales 53.25
Price to Cash Flow -11.59
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android